Calyxt, Inc. (CLXT)
(Delayed Data from NSDQ)
$15.70 USD
+0.19 (1.23%)
Updated May 3, 2019 04:00 PM ET
After-Market: $15.67 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$15.70 USD
+0.19 (1.23%)
Updated May 3, 2019 04:00 PM ET
After-Market: $15.67 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Calyxt (CLXT) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Calyxt (CLXT) delivered earnings and revenue surprises of 13.33% and 86%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Bears are Losing Control Over Calyxt (CLXT), Here's Why It's a 'Buy' Now
by Zacks Equity Research
Calyxt (CLXT) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Calyxt (CLXT) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Calyxt (CLXT) delivered earnings and revenue surprises of 6.67% and 36.67%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Calyxt (CLXT) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Calyxt (CLXT) delivered earnings and revenue surprises of 22.22% and 96.24%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Calyxt (CLXT) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Calyxt (CLXT) delivered earnings and revenue surprises of 17.39% and 42.28%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Inovio Pharmaceuticals (INO) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Inovio (INO) delivered earnings and revenue surprises of -51.52% and 301.44%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Global Blood Therapeutics (GBT) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Global Blood (GBT) delivered earnings and revenue surprises of -19.30% and 1.01%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Calyxt (CLXT) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Calyxt (CLXT) delivered earnings and revenue surprises of -26.32% and 69.48%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Will Calyxt (CLXT) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Calyxt (CLXT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Calyxt (CLXT) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Calyxt (CLXT) delivered earnings and revenue surprises of -10.53% and 50.00%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Calyxt (CLXT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Calyxt (CLXT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Calyxt (CLXT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Calyxt (CLXT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Clorox (CLX) Queues Up For Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Clorox (CLX) witnesses manufacturing and logistics costs. These along with higher selling and administrative costs might have hurt the bottom line in third-quarter fiscal 2021.
Calyxt (CLXT) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Calyxt (CLXT) delivered earnings and revenue surprises of -32.00% and 77.18%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Should You Buy Calyxt (CLXT) Ahead of Earnings?
by Zacks Equity Research
Calyxt (CLXT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Are You Looking for a Top Momentum Pick? Why Calyxt (CLXT) is a Great Choice
by Zacks Equity Research
Does Calyxt (CLXT) have what it takes to be a top stock pick for momentum investors? Let's find out.
Hain Celestial's (HAIN) Q2 Earnings Beat on Higher Margins
by Zacks Equity Research
Smooth execution of transformation plan aided Hain Celestial's (HAIN) second-quarter fiscal 2021 performance. It expects sustained margin growth for fiscal 2021.
Moving Average Crossover Alert: Calyxt (CLXT)
by Zacks Equity Research
Calyxt (CLXT) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
The Zacks Analyst Blog Highlights: BlackBerry, Calyxt, DAQO New Energy, Avis Budget Group and 3D Systems
by Zacks Equity Research
The Zacks Analyst Blog Highlights: BlackBerry, Calyxt, DAQO New Energy, Avis Budget Group and 3D Systems
5 High-Flying Stocks Set to Move Higher
by Sejuti Banerjea
These 5 stocks have good reason for further upside.
Here's Why Calyxt (CLXT) is a Great Momentum Stock to Buy
by Zacks Equity Research
Does Calyxt (CLXT) have what it takes to be a top stock pick for momentum investors? Let's find out.
What Makes Calyxt (CLXT) a New Strong Buy Stock
by Zacks Equity Research
Calyxt (CLXT) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Here's How Americans Are Regaining Confidence: 5 Picks
by Sanghamitra Saha
U.S. consumer confidence gained in May and beat the expectations of economists polled by Dow Jones.
Calyxt (CLXT) Moves to Strong Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Calyxt (CLXT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Agriculture Operations Outlook: Tariffs to Mar Organic Gains
by Rajani Lohia
The Zacks Agriculture - Operations industry should witness gains from wooing customers with organic solutions for crop production. Yet, tariff-related headwinds remain threats to top line.